Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
SHSE:688091'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -7.98 Med: 0.01 Max: 0.4
Current: 0.4
During the past 9 years, the highest Debt-to-EBITDA Ratio of Shanghai Yizhong Pharmaceutical Co was 0.40. The lowest was -7.98. And the median was 0.01.
SHSE:688091's Debt-to-EBITDA is ranked better than 74.7% of 676
companies
in the Drug Manufacturers industry
Industry Median: 1.64
vs SHSE:688091: 0.40
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Shanghai Yizhong Pharmaceutical Co Debt-to-EBITDA Related Terms
Shanghai Yizhong Pharmaceutical Co Debt-to-EBITDA Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shanghai Yizhong Pharmaceutical Co Debt-to-EBITDA Chart
For the Drug Manufacturers - Specialty & Generic subindustry, Shanghai Yizhong Pharmaceutical Co's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shanghai Yizhong Pharmaceutical Co Debt-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Shanghai Yizhong Pharmaceutical Co's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Shanghai Yizhong Pharmaceutical Co's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Jun. 2026) EBITDA data.
Shanghai Yizhong Pharmaceutical Co (SHSE:688091) has a Debt-to-EBITDA of 0.26 as of Jun. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Shanghai Yizhong Pharmaceutical Co. This is 2500% above median its historical median of 0.01. According to the industry distribution chart, Shanghai Yizhong Pharmaceutical Co ranks #171 out of 676 companies in the Drug Manufacturers industry, placing it in the top 25.3%.
Is Shanghai Yizhong Pharmaceutical Co's Debt-to-EBITDA too high?
Shanghai Yizhong Pharmaceutical Co's current Debt-to-EBITDA of 0.26 is 2500% above median its 10-year median of 0.01. The Drug Manufacturers industry median Debt-to-EBITDA is 1.64. Shanghai Yizhong Pharmaceutical Co's value of 0.26 is 84.1% below this industry median. Based on the distribution chart, Shanghai Yizhong Pharmaceutical Co ranks #171 out of 676 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Shanghai Yizhong Pharmaceutical Co has a GF Score™ of 57/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Shanghai Yizhong Pharmaceutical Co's Debt-to-EBITDA compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Shanghai Yizhong Pharmaceutical Co ranks #171 out of 676 companies for Debt-to-EBITDA. This puts Shanghai Yizhong Pharmaceutical Co in the upper half of its industry. The industry median Debt-to-EBITDA is 1.64. Shanghai Yizhong Pharmaceutical Co's value of 0.26 is 84.1% below this benchmark. While the company's 10-year median is 0.01 vs. the industry median of 1.64, Shanghai Yizhong Pharmaceutical Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Drug Manufacturers company?
The median Debt-to-EBITDA among Drug Manufacturers companies is 1.64, based on 676 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Shanghai Yizhong Pharmaceutical Co's current Debt-to-EBITDA of 0.26 is 84.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Shanghai Yizhong Pharmaceutical Co. For the Drug Manufacturers industry, the median Debt-to-EBITDA is 1.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shanghai Yizhong Pharmaceutical Co's current Debt-to-EBITDA is 0.26, which is 2500% above median its own 10-year median of 0.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shanghai Yizhong Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Shanghai Yizhong Pharmaceutical Co (SHSE:688091) is currently considered Fairly Valued. The stock's GF Value™ is ¥42.94, compared to a current price of ¥39.88 — trading 7.1% below its estimated fair value. The current Debt-to-EBITDA is 0.26, which is 2500% above median its 10-year median of 0.01 and 84.1% below the Drug Manufacturers industry median of 1.64. Shanghai Yizhong Pharmaceutical Co's overall GF Score™ is 57/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Shanghai Yizhong Pharmaceutical Co (SHSE:688091), the current Debt-to-EBITDA is 0.26 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shanghai Yizhong Pharmaceutical Co (SHSE:688091) Overvalued in 2026?
Based on GuruFocus' analysis, Shanghai Yizhong Pharmaceutical Co stock appears to be undervalued.
The current stock price of ¥39.88 is trading 7.1% below its estimated GF Value™ of ¥42.94.
GuruFocus considers Shanghai Yizhong Pharmaceutical Co to be Fairly Valued.
Key valuation signals for SHSE:688091:
Debt-to-EBITDA: 0.26 (2500% above median its 10-year median of 0.01)
GF Value™: ¥42.94 vs. price of ¥39.88 (7.1% below fair value)
Industry Position: 84.1% below the Drug Manufacturers median (#171 of 676)
No single metric tells the full story. See the SHSE:688091 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shanghai Yizhong Pharmaceutical Co Ltd is a pharmaceutical enterprise integrating research and development, production and sales. It is committed towards the development of new dosage forms of anti-tumor drugs and related products.
57GF Score
Get the complete analysis for SHSE:688091
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688091 has been successfully added to your 
